Bioactive nanomedicines for multidrug-resistant colorectal cancer: Actionable mechanisms, emerging particle classes, and translational barriers
Advanced Drug Delivery Reviews · 2026
DOI: 10.1016/j.addr.2026.115957 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Drug Delivery Reviews, 2026. Verfasst von Milad Rasouli und 3 weiteren Autor:innen. Beteiligte Einrichtung: The Research Institute of the McGill University Health Centre, McGill University, Montreal, Canada; School of Engineering Design and Innovation, The …. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Drug Resistance, Neoplasm, Antineoplastic Agents, Nanoparticles. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 217 Literaturangaben.
Abstract (Originalsprache)
Multidrug resistance (MDR) in colorectal cancer (CRC) arises from interacting tumour-cell, pharmacological and microenvironmental programmes that undermine both drug activity and delivery. Chemotherapy-associated MDR is the principal focus of this review, while resistance to targeted therapy and immunotherapy is considered where it directly affects delivery design or patient selection. Bioactive compounds can modulate several resistance pathways, but their translational value is constrained by poor solubility, instability, rapid metabolism and inadequate exposure at resistant lesions. This review critically examines when nanomedicine can make such mechanistic activity pharmacologically and translationally meaningful. We link resistance biology to delivery functions, evaluate bioactive chemosensitiser candidates against human exposure, compare major nanomedicine design strategies, and assess nano-bio interactions, repeat-dose safety, manufacturing and clinical positioning. Across the evidence, three limitations recur. First, concentrations associated with chemosensitisation for curcumin, resveratrol, epigallocatechin gallate and quercetin generally exceed measured human parent-analyte exposure. Second, many resistance claims rely on parental or poorly characterised models, whereas studies combining defined resistance provenance with functional mechanism and exposure confirmation remain uncommon. Third, human studies demonstrate feasibility, tissue exposure or treatment response, but not mechanism-specific reversal of CRC MDR by a bioactive compound or bioactive nanomedicine. Progress therefore depends less on adding new particle classes than on matching a necessary formulation function to a defined resistance or spatial barrier, quantifying active exposure in the relevant compartment, validating mechanism in appropriate models, and integrating repeat-dose safety, scalable manufacturing and biomarker-guided clinical development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Research Institute of the McGill University Health Centre, McGill University, Montreal, Canada; School of Engineering Design and Innovation, The Pennsylvania State University, University Park, PA 16801, USA; Nova Na…
- Department of Cell and Molecular Sciences, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran.
- Division of Experimental Medicine, Department of Medicine, McGill University, Montréal, Canada; Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, Canada.
- Department of Cell and Molecular Sciences, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran. Electronic address: divsalar@khu.ac.ir.
Zitieren
APA
Rasouli, M., Babaei, F., Fallahhosseini, N., & Divsalar, A. (2026). Bioactive nanomedicines for multidrug-resistant colorectal cancer: Actionable mechanisms, emerging particle classes, and translational barriers. Advanced Drug Delivery Reviews. https://doi.org/10.1016/j.addr.2026.115957
Vancouver
Rasouli M, Babaei F, Fallahhosseini N, Divsalar A. Bioactive nanomedicines for multidrug-resistant colorectal cancer: Actionable mechanisms, emerging particle classes, and translational barriers. Advanced Drug Delivery Reviews. 2026. doi:10.1016/j.addr.2026.115957
BibTeX
@article{Rasouli2026,
author = {Rasouli, Milad and Babaei, Fatemeh and Fallahhosseini, Nadia and Divsalar, Adeleh},
title = {Bioactive nanomedicines for multidrug-resistant colorectal cancer: Actionable mechanisms, emerging particle classes, and translational barriers},
journal = {Advanced Drug Delivery Reviews},
year = {2026},
doi = {10.1016/j.addr.2026.115957}
}
EUVIMED